Quotient completes Bioanalytical Facility

Quotient Bioresearch, a provider of early stage and specialist drug development services, has finished the £1.5m expansion to its Fordham, Cambridgeshire site.
The building work, which took place over the summer includes a new bioanalytical facility with a capacity for 30 mass spectrometers and new laboratories for immunoassay and cell-based work with biopharmaceuticals and biomarkers.

Dr Steve Pleasance, Managing Director of Bioanalytical Sciences at Quotient commented: “Our new facilities at Fordham will assist the continued growth of our services, supporting our customers in taking new and innovative approaches. I’d like to thank all those involved in delivering the project on time and on budget. This is a big step forward for Quotient and we’re all very excited about how it will expand our offering to our clients.”

Over 60 delegates attended a series of presentations and participated in lively debate during Quotients’s Autumn Seminar on Biomarkers and Decision-Making in Drug Development, held at the new facility on 4th October.